We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Silica-Based Nanoparticles Selectively Kill Lung Cancer Cells

By LabMedica International staff writers
Posted on 16 Mar 2015
A novel approach to the selective delivery of toxic chemotherapeutic agents is based on nanoparticles that sequester the drug until it is liberated by the action of specific proteases that are present in a high concentration inside lung cancer cells.

Investigators at the German Research Center for Environmental Health (Munich, Germany) constructed the nanoparticles—basically extremely small open-ended boxes—from mesoporous silica (containing pores with diameters between two and 50 nanometers) tightly capped at each end by avidin molecules linked by proteins sensitive to the action of the protease MMP9 (matrix metalloproteinase 9). More...
The nanoparticles were loaded with the cancer drug cisplatin, which was safely sequestered as long as the avidin-protein caps remained intact.

The justification for use of these nanoparticles was the fact that the protease MMP9 was overexpressed in tumors. It was known to enhance the metastatic potency of malignant cells and had been associated with poor prognosis of lung cancer.

The investigators studied the impact of cisplatin-containing nanoparticles on mouse tumors in vivo and on mouse and human lung tumors being grown in novel ex vivo three-dimensional lung tissue cultures.

They reported in the February 22, 2015, online edition of the journal ACS Nano that the MMP9-mediated release of cisplatin induced apoptotic cell death only in lung tumor regions of Kras mutant mice without causing toxicity in tumor-free areas or in healthy mice. The MMP9-responsive nanoparticles also allowed for effective combinatorial drug delivery of cisplatin and the proteasome inhibitor bortezomib, which had a synergistic effect on the therapeutic efficiency. The concentration of MMP9 in healthy lung tissue was too low to destroy the nanoparticles' protective layer and the drugs remained sequestered inside the nanocarriers.

"Using these nanocarriers we can very selectively release a drug such as a chemotherapeutic agent specifically at the lung tumor," said senior author Dr. Silke Meiners, a group leader at the German Research Center for Environmental Health. "We observed that the drug's effectiveness in the tumor tissue was 10 to 25 times greater compared to when the drugs were used on their own. At the same time, this approach also makes it possible to decrease the total dose of medicines and consequently to reduce undesirable effects."

Related Links:

German Research Center for Environmental Health



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.